
Quick Links
You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
                                    Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa | 
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa | 
|---|---|---|---|---|---|---|
东京与旧金山,2019年9月20日——安斯泰来制药公司(TSE:4503,总裁兼CEO:Kenji Yasukawa,Ph.D.,“安斯泰来”)与FibroGen, Inc. (Nasdaq:FGEN, Interim...
-FDA审评截止日期为2020年3月15日- 华盛顿波赛尔与东京,2019年9月16日——Seattle Genetics, Inc....
Read more about 美国食品与药品管理局批准对Enfortumab Vedotin治疗局部晚期或转移性尿路上皮癌的生物制剂许可申请进行优先审评
- 一项关键性试验中的首个试验性疗法,以解决在铂剂化疗与PD-1或PD-L1抑制剂治疗后晚期泌尿上皮癌患者未满足的需求- -...
Read more about 安斯泰来与Seattle Genetics宣布,抗体-药物偶联物Enfortumab Vedotin对最常见类型的晚期泌尿上皮癌(膀胱癌)患者的肿瘤反应率为44%
安斯泰来集团于2019年4月2日上午在AACR会议期间公布了III期ADMIRAL临床试验的结果,该项临床试验比较了XOSPATA®(gilteritinib)和补救化疗治疗FLT3突变的
